Dupont Capital Management’s Sage Therapeutics SAGE Stock Holding History

Dupont Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,083	Closed	-$156K	–	1826
2021 Q1	$156K	Hold	2,083	–	–	﹤0.01%	1313
2020 Q4	$180K	Buy	+2,083	New	+$154K	﹤0.01%	1150
2018 Q4	–	Sell	-4,500	Closed	-$636K	–	1216
2018 Q3	$636K	Buy	+4,500	New	+$695K	0.01%	676
2018 Q2	–	Sell	-3,002	Closed	-$484K	–	1029
2018 Q1	$484K	Hold	3,002	–	–	0.01%	682
2017 Q4	$494K	Sell	3,002 -10,526	-78%	-$1.02M	0.01%	657
2017 Q3	$843K	Hold	13,528	–	–	0.02%	562
2017 Q2	$1.08M	Hold	13,528	–	–	0.02%	508
2017 Q1	$961K	Hold	13,528	–	–	0.02%	534
2016 Q4	$691K	Hold	13,528	–	–	0.02%	586
2016 Q3	$623K	Buy	+13,528	New	+$551K	0.01%	540

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dupont Capital Management's SAGE Position: Q2 2021 in Review

Dupont Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 2,083 shares — an estimated $156K sold.

Dupont Capital Management first reported a position in SAGE in Q3 2016 and held it in 10 quarters. The position peaked at $1.08M in Q2 2017. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

Dupont Capital Management reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
Dupont Capital Management sold 2,083 Sage Therapeutics shares in Q2 2021, an estimated $156K.
Dupont Capital Management first reported a position in Sage Therapeutics in Q3 2016 and held it in 10 quarters.
Dupont Capital Management's Sage Therapeutics position peaked at $1.08M in Q2 2017.
256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Dupont Capital Management's 13F filing for Q2 2021, filed 30 Jul 2021.